The content on this site is intended for healthcare professionals only
Dr Chetan Dhamne speaks to ecancer about a randomised, double-blind trial evaluating acyclovir pre-exposure prophylaxis for varicella-seronegative children receiving intensive chemotherapy for haematolymphoid malignancies.
He reports that acyclovir reduced the incidence of varicella from 21.2% with placebo to 1.8%, representing a 90% relative reduction in infection.
Dr Dhamne explains that the trial was stopped early for efficacy after meeting its predefined statistical boundary, with no drug-related toxicity observed.
He highlights that oral acyclovir could provide a simple, safe and relatively inexpensive strategy for preventing varicella-related morbidity and treatment interruptions, particularly in resource-constrained paediatric oncology settings where exposure is difficult to control.
Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL
